Repligen Corp
RGEN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000730272
In the last 90 days, Repligen Corp insiders filed 0 open-market purchases and 5 sales; 506 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; 3 superinvestors hold it, including Maverick Capital and Duquesne Family Office.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $5.00M in total
- 5
- 13F holdersQ2 2026, +43 vs. previous quarter
- 506
- 13F valueReported value at the end of Q2 2026
- $9.62B
- Superinvestors holdingAt the end of Q2 2026
- 3
Price chart
Superinvestors holding RGEN, Q2 2026
3 superinvestors report holding Repligen Corp on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.2%
Repligen Corp's share of the portfolio
- Shares
- 77,400
- Value
- $10.6M
| Superinvestor | Weight | Value |
|---|---|---|
| Weitz Investment Management | 0.4% | $5.57M |
Latest insider trades
Open-market purchases and sales by Repligen Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 2026 (view filing)4:09 PM ET | Sep 24 | 1 day | Loeillot OlivierChief Executive Officer | SSale | −12.9K | $190.00 | −$2.46M | −21.1%48.4K after | 2 lots10b5-1 |
| Sep 22, 2026 (view filing)4:07 PM ET | Sep 21 | 1 day | Loeillot OlivierChief Executive Officer | SSale | −5.43K | $180.00 | −$976.7K | −10.1%48.4K after | 10b5-1 |
| Sep 8, 2026 (view filing)4:13 PM ET | Sep 4 | 4 days | Loeillot OlivierChief Executive Officer | SSale | −3.04K | $165.90 | −$503.5K | −5.9%48.4K after | 10b5-1 |
| Aug 21, 2026 (view filing)4:06 PM ET | Aug 20 | 1 day | Loeillot OlivierChief Executive Officer | SSale | −5.43K | $180.00 | −$976.7K | −9.1%54.2K after | 10b5-1 |
| Jul 17, 2026 (view filing)4:40 PM ET | Jul 16 | 1 day | Garland Jason KCFO | SSale | −530 | $150.00 | −$79.5K | −2.7%18.8K after | 10b5-1 |
| Jun 26, 2026 (view filing) | Jun 25 | 1 day | Garland Jason KCFO | SSale | −733 | $145.00 | −$106.3K | −3.6%19.4K after | 10b5-1 |
| Apr 22, 2026 (view filing) | Apr 21 | 1 day | Loeillot OlivierChief Executive Officer | SSale | −3.83K | $140.00 | −$536.5K | −6.6%54.2K after | 10b5-1 |
| Dec 18, 2025 (view filing) | Dec 17 | 1 day | Dawes Karen ADirector | SSale | −275 | $161.00 | −$44.3K | −0.3%91.8K after | |
| Nov 26, 2025 (view filing) | Nov 25 | 1 day | Loeillot OlivierChief Executive Officer | SSale | −7.04K | $170.00 | −$1.20M | −16.4%35.9K after | 10b5-1 |
| Nov 19, 2025 (view filing) | Nov 18 | 1 day | Bylund JamesChief Operating Officer | SSale | −2.19K | $151.21 | −$331.3K | −9.2%21.5K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Repligen Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,384,938 | $747.2M | 0.01% | −608,116−10.1% | Reduced |
| FMR LLC | 3,326,690 | $462.2M | 0.02% | +439,904+15.2% | Added |
| United Capital Financial Advisers, LLC | 2,790,650 | $380.8M | 2.10% | +16,670+0.6% | Added |
| Vanguard Capital Management LLC | 2,411,171 | $329.0M | 0.01% | +14,660+0.6% | Added |
| Vanguard Portfolio Management LLC | 2,312,825 | $315.6M | 0.01% | +7,731+0.3% | Added |
| Maverick Capital LtdSuperinvestorMaverick Capital | 1,984,554 | $270.8M | 2.44% | +465,749+30.7% | Added |
| State Street Corp | 1,800,530 | $261.0M | 0.01% | +23,245+1.3% | Added |
| Price T Rowe Associates Inc | 1,752,274 | $239.1M | 0.02% | −3,125,867−64.1% | Reduced |
| Massachusetts Financial Services Co | 1,617,021 | $220.6M | 0.07% | +219,506+15.7% | Added |
| Wasatch Advisors Inc | 1,590,251 | $217.0M | 1.42% | +346,720+27.9% | Added |